SCHEMBL23928465

SCHEMBL23928465

CCCCCCN(C)C(=O)C(CCC)CCCCC

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.46
GRIK1 P39086 2/20 0.41
GRIK2 Q13002 2/20 0.41
GPR84 Q9NQS5 7/20 0.40
FFAR1 O14842 1/20 0.40
EPHX2 P34913 4/20 0.40
MAPT P10636 1/20 0.39
LCK P06239 1/20 0.39
PPARD Q03181 1/20 0.39
ZDHHC20 Q5W0Z9 1/20 0.39
ZDHHC2 Q9UIJ5 1/20 0.39
DNM1 Q05193 1/20 0.39
SLC1A2 P43004 1/20 0.39
SLC1A1 P43005 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23928464 0.96 EPHX2 (0.41) CA2GPR84FFAR1EPHX2DNM1
SCHEMBL29180336 0.96 CA2 (0.48) CA2GRIK1GRIK2GPR84FFAR1
SCHEMBL25319726 0.93 LMNA (0.43) CA2GRIK1GRIK2GPR84FFAR1
SCHEMBL25317185 0.91 S1PR2 (0.46) CA2GRIK1GRIK2GPR84FFAR1
SCHEMBL25698920 0.90 CA2 (0.47) CA2GRIK1GRIK2GPR84FFAR1
SCHEMBL24764590 0.90 CA2 (0.47) CA2GRIK1GRIK2GPR84FFAR1
SCHEMBL13003586 0.89 CA2 (0.48) CA2GRIK1GRIK2GPR84FFAR1
SCHEMBL25317535 0.89 CA2 (0.40) CA2GRIK1GRIK2GPR84FFAR1
SCHEMBL24340301 0.86 CA2 (0.46) CA2GRIK1GRIK2GPR84FFAR1
SCHEMBL20795803 0.86 CA2 (0.46) CA2GRIK1GRIK2GPR84FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240410034-A1 CYCLIC AMINE MONOAMIDES FOR EXTRACTING URANIUM(VI) AND PLUTONIUM(IV) AND FOR SEPARATING THEM WITHOUT REDUCING PLUTONIUM(IV) Commissariat à l'énergie atomique et aux énergies alternatives (FR) 2024-12-12 US disclosed
CN-118354828-A Cyclic amine monoamides for extracting uranium (VI) and plutonium (IV) and for separating them without reduction of the plutonium (IV) 原子能与替代能源委员会 2024-07-16 CN disclosed
WO-2023067273-A1 CYCLIC AMINE MONOAMIDES FOR THE EXTRACTION OF URANIUM(VI) AND PLUTONIUM(IV) AND FOR THE SEPARATION THEREOF WITHOUT REDUCTION OF THE PLUTONIUM(IV) COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2023-04-27 WO disclosed
US-11578031-B2 Dissymmetric N,N-dialkylamides used particularly for separating uranium(VI) from plutonium(IV), synthesis thereof and uses of same COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÊNERGIES ALTERNATIVES (FR) 2023-02-14 US disclosed
US-20210332002-A1 DISSYMMETRIC N,N-DIALKYLAMIDES USED PARTICULARLY FOR SEPARATING URANIUM(VI) FROM PLUTONIUM(IV), SYNTHESIS THEREOF AND USES OF SAME ORANO CYCLE (FR) 2021-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240410034-A1 CYCLIC AMINE MONOAMIDES FOR EXTRACTING URANIUM(VI) AND PLUTONIUM(IV) AND FOR SEPARATING THEM WITHOUT REDUCING PLUTONIUM(IV) PADI2, PADI4, PADI1 CA2 2313/4885GRIK1 2434/4885GRIK2 1845/4885
US-11578031-B2 Dissymmetric N,N-dialkylamides used particularly for separating uranium(VI) from plutonium(IV), synthesis thereof and uses of same NOS2, NOS1, NOS3 CA2 2594/4885GRIK1 3399/4885GRIK2 3359/4885
US-20210332002-A1 DISSYMMETRIC N,N-DIALKYLAMIDES USED PARTICULARLY FOR SEPARATING URANIUM(VI) FROM PLUTONIUM(IV), SYNTHESIS THEREOF AND USES OF SAME NOS2, NOS1, NOS3 CA2 2594/4885GRIK1 3399/4885GRIK2 3359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.